Beta-blockers and amiodarone for the primary prevention of sudden cardiac death
- 33 Downloads
Sudden cardiac death remains a major public health care problem, generally occurring in patients with ventricular dysfunction. Beta-blockers, already of proven benefit for patients after myocardial infarction, have recently been shown to improve functional status and mortality outcomes in patients with heart failure. Amiodarone, a potent antiarrhythmic drug, was recently studied in a number of randomized clinical trials involving patients with heart failure and patients after myocardial infarction. Routine use of amiodarone cannot be recommended in these patient groups, but serious adverse outcomes were not observed. When antiarrhythmic drug therapy is required, amiodarone is the drug of choice for patients with structural heart disease.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Myerburg RJ, Castellanos A: Cardiac arrest and sudden cardiac death. In In Heart Disease: A Textbook of Cardiovascular Medicine. Edited by Braunwald E. Philadelphia: WB Saunders; 1997:742–779.Google Scholar
- 4.Engelstein ED, Zipes DP: Sudden cardiac death. In The Heart, Arteries and Veins. Edited by Alexander RW, Schlant RC, Fuster V New York: McGraw-Hill; 1998 1081–1112.Google Scholar
- 5.Myerbur RJ, Kessler KM, Castellanos A, et al.: Sudden cardiac death: Epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993, 119:1187–1197.Google Scholar
- 18.The MIAMI Trial Research Group: Metoprolol in Acut Myocardial Infarction (MIAMI): a randomized placebocontrolled international trial. Eur Heart J 1985, 6:199–226.Google Scholar
- 30.CIBIS Investigators and Committees: A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994, 90:1765–1773.Google Scholar
- 31.CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999, 353 9–13. This multicenter, double-blind, randomized study showed a significant reduction in all-cause mortality and sudden cardiac death for patients with symptomatic heart failure. The etiology of heart failure did not influence the results.CrossRefGoogle Scholar
- 32.MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001–2007. This paper provided evidence that patients with chronic heart failure experience significant reduction of all-cause mortality, worsening heart failure and sudden cardiac death if metoprolol is added to an accepted heart failure regimen.CrossRefGoogle Scholar
- 34.Australia-New Zealand Heart Failure Research Collaborative Group: Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995, 92:212–218.Google Scholar
- 48.Janse MJ, Malik M, Camm AJ, et al.: Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substud of EMIAT. Eur Heart J 1998, 9:85–95. This paper provides a post-hoc analysis of baseline parameters from patients in the EMIAT study. The authors attempt to identify subgroups that might benefit or be harmed from treatment with amiodarone.CrossRefGoogle Scholar
- 50.Klein H, Auricchio A, Reek S, et al.: New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999, 83:91D-97D. This study is aimed at evaluating whether patients with ischemic or nonischemic cardiomyopathy who are in NYHA II or III failure will experience a reduction in overall mortality if provided with an implantable defibrillator. Amiodarone will be used as alternative treatment modality.PubMedCrossRefGoogle Scholar